10
Disclosures
Feb 2, 2026 — May 25, 2026
Date Range
PRIME
Market Segment
Pharmaceutical
Sector

Disclosures

DateTypeHeadlinePDF
May 25 M&A ASKA Pharmaceutical Holdings Pharma to Seek Shareholder Approval for Anti-Takeover Measures Amid Dalton Group Threat PDF
May 25 Corporate Action ASKA Pharmaceutical Holdings selects new auditor ahead of annual meeting PDF
May 25 Corporate Action ASKA Pharmaceutical Holdings Pharmaceutical to Amend Executive Stock Compensation Plan; Introduce Outside Director Program PDF
May 11 Other ASKA Pharmaceutical Holdings appoints new directors and executives PDF
May 11 Business Transfer ASKA Pharmaceutical Holdings Announces Business Transfer PDF
May 11 Earnings ASKA Pharmaceutical Holdings Reports Strong Q4 Results; Raises FY27 Outlook PDF
May 11 Earnings ASKA Pharmaceutical Holdings Reports FY26 Revenue of 71.1 billion, Up 11% PDF
Mar 23 Legal ASKA Pharmaceutical Holdings Pharma Sets Long-Term Vision 2035 and Mid-Term Plan 2028 PDF
Feb 2 Earnings ASKA Pharmaceutical Holdings Co., Ltd. Reports Q3 FY2026 Earnings Presentation: Revenue of 64.1 billion PDF
Feb 2 Earnings ASKA Pharmaceutical Holdings Co., Ltd. Q3 FY2026 Earnings Presentation: Revenue of 49.9 billion, +1.0% YoY PDF

Disclosure Types

Earnings: 4 Corporate Action: 2 M&A: 1 Other: 1 Business Transfer: 1 Legal: 1